CARCINOMA, NON-SMALL-CELL LUNG

This trial tests a new drug, UCB4594, designed to help the immune system attack cancer cells by targeting a protein called HLA-G found on many tumors. It is for people with advanced solid cancers that have not responded to standard treatments. The study aims to find the safest do…

This study tests a new drug called LY4175408 in people with advanced lung, endometrial, or breast cancer that has spread. The drug is designed to target and kill cancer cells while sparing healthy ones. The goal is to check safety, how the drug moves through the body, and whether…

This study tests a new gene therapy (quaratusugene ozeplasmid) added to the standard drug osimertinib for people with advanced EGFR-mutant non-small cell lung cancer that has stopped responding to osimertinib alone. The gene therapy aims to restore a tumor-suppressing gene. About…

This study tests whether adding an experimental drug (V940) to the standard immunotherapy (pembrolizumab) after surgery can help prevent non-small cell lung cancer from returning. It includes 680 adults whose tumors did not fully disappear with pre-surgery treatment. Participants…

This study compares a new drug, BAT3306, to the approved drug Keytruda in people with stage IB-IIIA non-small cell lung cancer whose tumors were completely removed by surgery. The goal is to see if BAT3306 works similarly in the body as an additional treatment after surgery. Abou…

This study tests whether adding an experimental drug (JNJ-90301900) to standard chemoradiation, followed by maintenance immunotherapy (durvalumab), can shrink tumors more effectively in people with locally advanced, inoperable stage III non-small cell lung cancer. About 130 parti…

This study tests a combination of two drugs, amivantamab and olomorasib, in people with a specific type of advanced lung cancer (KRAS G12C mutation) that has spread. The goal is to find the best dose and see if the combo can shrink tumors or slow their growth. About 60 participan…

This study tests whether a combination of two drugs (sacituzumab and zimberelimab) can prevent lung cancer from coming back after surgery. It is for people with stage IB to IIIB non-small cell lung cancer whose tumor did not fully disappear after pre-surgery treatment. About 129 …

This early-stage study tests a new drug, PF-08046054/SGN-PDL1V, in people with advanced solid tumors that have spread or can't be removed. The drug is given alone or with pembrolizumab to see if it's safe and what side effects occur. About 714 participants with cancers like lung,…

This phase 3 trial tests whether adding the targeted drug adagrasib to standard immunotherapy and chemotherapy helps people with a specific genetic form of advanced lung cancer (KRAS G12C mutation) live longer without their disease worsening. About 630 adults who have not had pri…

This early-stage study tests a new drug called PF-08046876 in people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. The drug is designed to stick to cancer cells and kill them directly. The main goals are to check safety, find the best dose, an…

This study tests a new drug, BMS-986504, in people with advanced or spreading non-small cell lung cancer that has a specific genetic change (MTAP deletion) and has stopped responding to other treatments. The goal is to see if the drug can shrink tumors or control the disease. Abo…

This study tests whether adding a very precise, high-dose radiation boost (CyberKnife) after standard chemotherapy and radiation can help people with locally advanced non-small cell lung cancer live longer without the cancer growing. About 42 adults with stage III lung cancer tha…

This early-stage study tests a new drug called AST-201 in about 70 adults with advanced solid tumors that have a specific protein (GPC3). The main goal is to check the drug's safety and find the right dose. Researchers will also look at how the drug moves through the body and whe…

This early-phase trial tests an experimental drug, DM005, in about 136 people with advanced solid tumors (like lung, head and neck, or other cancers) that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see how wel…

This study tests an experimental drug called N17350 for people with advanced solid tumors that have not responded to standard treatments. The drug is injected directly into tumor lesions every two weeks for up to 12 weeks. Researchers aim to find the safest and most effective dos…

This study tests a new treatment for people with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer) that has spread to the lining of the brain and spinal cord (leptomeningeal metastasis) and has stopped responding to the drug osimertinib. The treatment combin…

This early-phase study tests a new drug (JNJ-86974680) alone or with another drug and radiation for people with advanced non-small cell lung cancer. The main goal is to find a safe dose and check for side effects. About 126 adults with stage IIIB or IV lung cancer will take part.

This study tests whether adding the experimental drug olomorasib to standard immunotherapy helps people with a specific genetic subtype of non-small cell lung cancer (KRAS G12C mutation). About 700 adults whose cancer was either surgically removed or cannot be removed will receiv…

This study tests whether adding a new targeted drug (LY3537982) to standard treatments helps people with a specific genetic subtype of advanced non-small cell lung cancer (KRAS G12C mutation). About 1,264 participants will receive either the new drug combo or standard therapy. Th…

This study tests two drug combinations for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation). One group gets a new drug (amivantamab) plus a targeted pill (lazertinib) as their first treatment. Another group gets amivantamab with c…

This study tests different drug combinations, including the immunotherapy pembrolizumab, in people with advanced non-small cell lung cancer. It uses an "umbrella" design, meaning participants are grouped based on their tumor type and genetics. The goal is to find which treatments…

This study tests a subcutaneous (under-the-skin) form of the drug amivantamab in people with advanced EGFR-mutated non-small cell lung cancer. About 520 participants will receive the drug in different combinations to see if it shrinks tumors and how safe it is. The goal is to con…

This study tests a new medicine called PF-08634404 combined with other cancer drugs in people with advanced non-small cell lung cancer that has spread and cannot be removed by surgery. The goal is to see if the combination is safe and can shrink tumors. About 162 adults will rece…

This study tracks 800 adults in China who have ALK-positive early-stage lung cancer and took alectinib pills after surgery to remove their tumor. The goal is to see how long they stay cancer-free in real-world settings. Alectinib is a targeted therapy that blocks cancer growth, b…

This study tests whether adding a new drug (Sigvotatug Vedotin) to standard immunotherapy (pembrolizumab) helps people with advanced non-small cell lung cancer that has high PD-L1 levels live longer or delay cancer growth. About 714 participants will receive either the combo or p…

This study looks at whether a simple blood test that tracks tumor DNA can help doctors decide if patients with advanced non-small cell lung cancer can be treated with immunotherapy alone or need chemotherapy added. About 108 adults with newly diagnosed stage IV lung cancer and hi…

This early-stage study tests a new drug called AZD9592, alone or with other cancer treatments, in people with advanced solid tumors (lung, head & neck, or colorectal cancer that has spread). The main goals are to check safety, find the right dose, and see if it shrinks tumors. Ab…

This study tests an experimental drug called LY3537982 in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drug is safe and shrinks tumors. About 540 adults with lung, colorectal, endometrial, ovarian, pancreatic, or bile duct c…

This study is for people with stage IV non-small cell lung cancer who have not had any prior treatment. It tests whether adding new experimental drugs to the standard immunotherapy (pembrolizumab) with or without chemotherapy can shrink tumors or control the disease better. About…

This study tests whether adding an experimental drug called LP-300 to standard chemotherapy can help people who never smoked but have advanced lung cancer that stopped responding to targeted therapy. About 90 participants will receive either the drug combo or chemo alone. The goa…

This early-stage trial tests a drug called sigvotatug vedotin, alone or with other medicines, in people with advanced solid tumors like lung, head and neck, or breast cancer. The main goal is to check safety and find the right dose. About 1,000 participants will join this study t…

This study compares a new drug, rilvegostomig, to the current standard treatment, pembrolizumab, for people with advanced non-small cell lung cancer that has high levels of PD-L1. The goal is to see if the new drug works better at helping people live longer or stopping the cancer…

This study tests an inhaled form of the drug azacytidine, given alongside standard chemotherapy and immunotherapy, for people with early-stage non-small cell lung cancer that can be removed by surgery. The goal is to find the safest and most effective dose and see if this combina…

This study compares two treatments given before surgery for non-small cell lung cancer: immunotherapy (cemiplimab) plus chemotherapy versus immunotherapy plus targeted radiation. About 112 people with stage IB to III lung cancer will take part. After surgery, all participants con…

This study tests two drugs, vemurafenib and cobimetinib, already approved for melanoma, in adults with other rare cancers that have a specific BRAF V600 gene change. About 30 people will take the drugs to see if their tumors shrink or stop growing. The goal is to find new uses fo…

This study tests a new experimental drug, PF-07934040, for people with advanced solid tumors that have a KRAS gene mutation. The drug is taken as a pill twice a day, either alone or with other anti-cancer medicines given by IV. The goal is to find the safest dose and see if the d…

This study tests whether a new drug, PF-08634404, combined with chemotherapy works better than the current standard treatment (pembrolizumab plus chemo) for adults with advanced non-small cell lung cancer. About 1,410 participants will be randomly assigned to receive either the n…

This phase 3 study tests whether a new drug called THIO, given before the immunotherapy cemiplimab, can help people with advanced non-small cell lung cancer whose disease has worsened after two prior treatments. About 300 adults will be randomly assigned to receive either the THI…

This study tests whether adding two immunotherapy drugs (durvalumab and tremelimumab) to standard chemotherapy is safe and effective for people with HIV who have advanced non-small cell lung cancer. About 18 participants will receive the treatment and be monitored for side effect…

This pilot study tests whether giving a higher dose of proton therapy to the lung tumor is safe for people with stage III non-small-cell lung cancer who are also receiving chemotherapy. About 87 participants will receive the higher dose during the same number of treatment visits …

This study tests a new drug called LY4170156 in people with advanced solid tumors, such as ovarian, lung, and breast cancers. The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has two parts: first to find the safest dose, then to see how w…

This study tests an experimental drug called PF-08046050 in people with advanced solid tumors (cancers that have spread or can't be removed). The drug is designed to stick to cancer cells and kill them. The main goal is to check safety and find the right dose. About 914 adults wi…

This study is for people with advanced nonsquamous non-small cell lung cancer that has spread and no longer responds to standard immunotherapy or chemotherapy. Researchers are testing two antibody-drug conjugates (ADCs) — targeted drugs that deliver treatment directly to cancer c…

This study compares standard bronchoscopy (a lung scope procedure) with and without a special laser imaging tool called nCLE. The goal is to see if nCLE helps doctors place the biopsy needle more accurately, leading to a clear diagnosis more often. About 208 adults with suspiciou…

This study is testing a new supportive care program called POISE for people with advanced non-small cell lung cancer. The program includes four visits with a specially trained palliative care clinician to help patients cope with uncertainty and manage their cancer journey. Resear…

This study tracks 380 people with a common type of advanced lung cancer (EGFR-mutated NSCLC) who are already receiving the approved drug amivantamab as part of their normal care. Researchers will collect information on how long patients stay on treatment and how well it controls …

This study monitors the safety and effectiveness of brigatinib in adults with advanced ALK-positive non-small cell lung cancer in South Korea. Researchers will track side effects and tumor response in 257 patients who start brigatinib for the first time. The goal is to see how we…

This study is collecting information and biological samples from 730 adults newly diagnosed with lung cancer. Researchers want to see how patients respond to treatments in everyday medical practice, not just in strict clinical trials. The goal is to better understand the disease …

This study is testing whether a team of different specialists (like surgeons, cancer doctors, and geriatricians) can create better, personalized treatment plans for older adults (ages 60-90) with lung cancer. The goal is to see if this team approach helps people live longer witho…

This study is collecting information from 3,750 adults with lung cancer across 21 hospitals in Algeria. Researchers will look at patient backgrounds, tumor types, treatments, and outcomes to understand how lung cancer is managed in real-world settings. No new treatments are teste…